Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05433142 · ClinicalTrials.gov registry record · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
A Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Xencor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 307
- Enrollment target
- 20
- Study locations
NCT05433142: Recruiting Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Xencor.
NCT05433142 is a Phase 1 study of Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Xencor. The registered enrollment target is 307 participants, above the 196-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05433142, a Phase 1 study of Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Xencor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 307 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Primary Outcome
Safety and tolerability as assessed by incidence of TEAEs; incidence of clinically significant changes in safety laboratory tests, PE findings, vital signs, and ECGs; incidence and severity of CRS
Conditions Studied
Interventions
- BIOLOGICAL XmAb819
Study Locations (20)
California
- Xencor Investigative Site - Duarte
- Xencor Investigative Site - Sacramento
Illinois
- Xencor Investigative Site - Chicago
- Xencor Investigative Site - Chicago
New York
- Xencor Investigative Site - New York
- Xencor Investigative Site - New York
North Carolina
- Xencor Investigative Site - Charlotte
- Xencor Investigative Site - Durham
Ohio
- Xencor Investigative Site - Cincinnati
- Xencor Investigative Site - Columbus
Arizona
- Xencor Investigative Site - Phoenix
Connecticut
- Xencor Investigative Site - New Haven
Florida
- Xencor Investigative Site - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT05433142 shows while recruiting
NCT05433142 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which XmAb819 is the first listed.
NCT05433142 names 20 study sites across 15 states, led by California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05433142 about?
NCT05433142 is a clinical study titled "Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma". The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
What is the current status of trial NCT05433142?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 307 participants. The study started on 2022-06-13. Estimated completion is 2028-12.
What conditions does trial NCT05433142 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT05433142?
The interventions under investigation include: XmAb819 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05433142?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05433142 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05433142's enrollment target sits among peer trials
307 7th of 45 higher than 39 of 45 other Clear Cell Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI